

In re Application of: OXVIG, et al.

Serial No.: 09/983,025

Filed: October 22, 2001

For: PREGNANCY ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2)

Confirmation No.: 7756

Art Unit: 1652


Examiner: RAMIREZ, D.

Washington, D.C.

Atty.'s Docket: OXVIG=1A

Date: January 5, 2005

U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, Mail Stop AF  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202  
Sir:



Transmitted herewith is an [XX] Amendment After Final Rejection, Replacement Sheet and Annotated Marked-Up Drawings Fig. 3, and Sequence Listing (paper and CRF) in the above-identified application.

[ ] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

[XX] Small entity status of this application under 37 CFR 1.9 and 1.27 has been previously asserted.

[ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

The fee has been calculated as shown below:

| (Col. 1)                                       |                                  | (Col. 2) |                                 | (Col. 3) |               | Small Entity |                | Other Than a Small Entity |                |
|--|----------------------------------|----------|---------------------------------|----------|---------------|--------------|----------------|---------------------------|----------------|
|  | Claims Remaining After Amendment |          | Highest No. Previously Paid For |          | Present Extra | Rate         | Additional Fee | Rate                      | Additional Fee |
| Total  | 46                               | Minus    | 64                              | 0        |               | x 25         | \$             | x 50                      | \$             |
| Indep.   | 5                                | Minus    | 5                               | 0        |               | x100         | \$             | x200                      | \$             |
| First Presentation of Multiple Dependent Claim |                                  |          |                                 |          |               | 180          | \$             | +360                      | \$             |
| TOTAL ADDITIONAL CLAIMS FEE                    |                                  |          |                                 |          |               |              | \$             | Total                     | \$             |

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petit

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[XX] First - \$ 60.00  
[ ] Second - \$ 225.00  
[ ] Third - \$ 510.00  
[ ] Fourth - \$ 795.00  
[ ] Fifth - \$ 1080.00

Other Than Small Entity

Response Filed Within

[ ] First - \$ 120.00  
[ ] Second - \$ 450.00  
[ ] Third - \$ 1020.00  
[ ] Fourth - \$ 1590.00  
[ ] Fifth - \$ 2160.00

[ ] Less fees (\$ ) already paid for months extension of time on .

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ . A duplicate copy of this sheet is attached.

[ ] A check in the amount of \$ is attached (check no. ).

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$60.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case.

This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

Facsimile: (202) 737-3528  
Telephone: (202) 628-5197

By:

IVER P. COOPER  
Registration No. 28,005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

OXVIG, et al.

Serial No.: 09/983,025

Filed: October 22, 2001

For: PREGNANCY ASSOCIATED  
PLASMA PROTEIN-A2  
(PAPP-A2)



Art Unit: 1652

Examiner: RAMIREZ, D.

Washington, D.C.

January 5, 2005

Docket No.: OXVIG=1A

Confirmation No.: 7756

AMENDMENT AFTER FINAL REJECTION

U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, Mail Stop AF  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202

S i r :

In response to the final rejection, please enter the following amendments and remarks.

**Amendments to the drawings** are reflected in the attached Replacement Sheet.

**Amendments to the Specification** are discussed on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks** begin on page of this paper.